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DEEP BRAIN STIMULATION AS ADJUVANT THERAPY FOR ALZHEIMER’S 
DISEASE 
JONATHAN ANDRADE 
ABSTRACT 
 Alzheimer’s disease (AD) is the neurodegenerative disease responsible for the 
majority of dementia cases across the United States. Its pathology involves the 
accumulation of protein plaques in areas of the brain directly involved with learning and 
memory formation, causing cognitive impairments and loss of independence in everyday 
life. Deep brain stimulation (DBS) is a relatively young field in medicine that has gained 
a great deal of traction with its efficacious clinical outcomes in neurological diseases 
including Parkinson’s disease, epilepsy, depression and obsessive-compulsive disorder. 
More recently, researchers have sought to discover the proper application of DBS to 
improve the formation of episodic memory to provide a comparable or superior therapy 
for AD. Many experiments have been performed using different electrical parameters, 
hardware, or locations stimulated in the brain, which produced mixed results for benefits 
in memory reinforcement. Of the various brain structures available to target, the 
Entorhinal Cortex (EC) has been shown to lead to numerous positive outcomes. 
Additionally, one study used a novel approach, applying DBS in response to the neural 
activity of the individual brain during memory encoding tasks, which produced 
improvements in memory performance. This proposal aims to use these modalities in 
concert – a closed-loop stimulation approach that monitors neural activity and targeting 
the EC – in AD dementia patients to act as an adjuvant therapy to current 
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acetylcholinesterase inhibitor medications that provide weak efficacy when used alone. 
This will be conducted in a 2 year, multicenter, double-blind, randomized controlled 
clinical trial comparing treatment with dual therapy consisting of DBS and an 
acetylcholinesterase inhibitor, to those with acetylcholinesterase inhibitor monotherapy. 
Participants will have mild or moderate AD at baseline, evaluated using the Mini-Mental 
State Examination and their progress in both experimental arms will be recorded using 
the 13 item Alzheimer’s Disease Assessment Subscale-Cognitive over a 2-year period. 
Investigators will study the primary outcome of delaying cognitive decline, with 
secondary effects involving the differences between age groups, stages of AD and how 
frequently stimulation was received in those within the DBS and standard therapy group. 
The results from this study have the potential to further improve future approaches 
involving DBS in the treatment of AD dementia, as the projected number of those 
affected by the disease continues to grow with advances in modern medicine.   
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INTRODUCTION 
Background 
Dementia is a progressive neurological disease that has been growing in prevalence on a 
global scale and, without a sufficient mode of therapy available to slow its rate of 
incidence, millions more will be affected annually as medical interventions improve and 
further lengthen the human life span.1 Alzheimer’s Disease (AD) is the most common 
dementia pathology with up to 60-80% of dementia cases originating from AD. Dementia 
due to AD involves an insidious onset spanning months or years, a witnessed cognitive 
decline and most commonly the inability to retain learned or recently presented 
information. As of 2017, 5.5 million Americans encompassing all ages are estimated to 
have AD dementia. The prevalence of AD dementia in the early-onset group or people 
younger than age 65 years is 4%, with the percentage rising as people continue to age; 
3% between ages 65-74, 17% between 75-84 years and 32% of people 85 years and 
above have AD.1 Without a cure or method of slowing its progression, the projected 
prevalence of AD will increase to 11-16 million cases by the year 2050.2 It can be 
difficult to perform a diagnosis of Alzheimer’s dementia due to its multiple features, 
stages and the reliance of others to bring these individuals to undergo medical evaluation, 
since disease progression is often invisible to those who are diagnosed. Thus, AD 
dementia is estimated to be underdiagnosed and, therefore, reported prevalence may be 
underestimated. 
 The pathology of AD is multi-faceted including the accumulation of beta-amyloid 
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 (Ab) 42 peptide plaques and an abnormal hyperphosphorylated form of tau protein in the 
brain that directly inhibit the natural function of neurons. The former prevents signals 
from being transferred between neurons and the latter disrupts necessary maintenance 
processes within the neurons themselves.1 Together, they promote an accelerated 
cognitive decline in those with AD, causing dementia and loss of their independence. 
Statement of the Problem 
Despite minor cognitive benefits from single or combination pharmacologic therapy for 
AD, there is insufficient evidence of a significant outcome from these approaches.3 
Between 2002 and 2012, only 1 of 244 drugs tested for AD therapy successfully received 
Food and Drug Administration (FDA) approval, indicating the difficulty in producing 
viable and safe pharmacologic therapies for the disease. Thus, alternative measures, such 
as deep brain stimulation (DBS), which has proven to have substantial efficacy in treating 
other neurodegenerative illnesses, must be investigated. The use of DBS in treating AD 
has been studied for some time with inconsistent outcomes due to varying approaches 
with respect to timing of DBS administration and the location in the brain. This study 
aims to improve precision in the timing of DBS using personalized measurements of 
human learning processes and focus application to the entorhinal cortex (EC), a crucial 
structure in the memory processing network.  
Hypothesis 
Acetylcholinesterase inhibitors paired with stimulation of the EC administered at a 
strategic point in memory processing that is unique to each participant will slow the 
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progression of cognitive decline in those with mild to moderate AD compared to 
pharmacological therapy alone. 
Objectives and specific aims 
With the precedent for the efficacy and safety set by the use of DBS for modulating and 
reinforcing neural pathways in neurodegenerative illnesses, the objective of this study is 
to determine whether DBS is a viable therapy for mild to moderate AD. Specific aims 
include: 
• To review the evidence involving DBS as a therapy for AD. 
• To investigate whether DBS of the EC produces memory enhancement. 
• To compare the effects on cognition with DBS to that with acetylcholinesterase 
inhibiters alone and evaluate its efficacy as an adjuvant to standard 
pharmacological therapy. 
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REVIEW OF THE LITERATURE 
Overview 
Memory formation  
In the human brain, there is a network, rather than a single structure responsible for 
recording memories, located predominantly within the cortices of the medial temporal 
lobe (MTL) and centered around the hippocampus. This thesis will primarily focus on 
episodic or declarative type memories. These memories, as described by Tulving, are 
unique in having information about the exact time and place of where they were 
experienced.4 In other words, it must hold the context in which the memory was formed. 
Through functional imaging, lesion and anatomical studies in humans and animal models, 
it has been discovered that the MTL remains mostly preserved across mammalian 
species. The MTL consists of the following structures: the amygdala, hippocampus and 
the adjacent parahippocampal, entorhinal and perirhinal cortices. The hippocampus can 
be further divided into Cornu ammonis (CA) regions 1-4, dentate gyrus and the 
subiculum. The principal sources of afferent and efferent information involving the 
hippocampus are made up of the perforant and fornix pathways.5 Figure 1 outlines the 
MTL circuitry and the flow of information through it. Stimuli entering various sensory 
cortices communicate initially with the perirhinal and parahippocampal cortical areas, 
both of which are parallel passages. They converge onto the neurons of the EC, which 
transmits the impulse to both the dentate gyrus and CA 3 through the perforant pathway 
and simultaneously through the direct pathway to the CA 1 hippocampal subregions. The 
hippocampus shares efferent and afferent routes for information exchange with the EC, in 
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addition to structures outside of the MTL such as the septal nuclei, anterior nuclei of the 
thalamus, the hypothalamus and the nucleus basalis of Meynert (NBM) through the 
branches of the fornix white matter pathway.  
 
Figure 1: Circuitry of the MTL adapted from Suthana et al. (2014)5 
 
The single most significant regulatory track in the cerebral cortex is composed of 
cholinergic afferents, which are crucial to the learning and memory forming process. This 
is evidenced by the hippocampus, amygdala, and the EC having the greatest density of 
cholinergic innervation across all of the human brain. Further support for the importance 
of acetylcholine has been shown in studies where disrupting cholinergic expression 
through pharmacologic and lesion methods resulted in episodic memory impairment in 
humans and animals alike.6,7 Acetylcholine’s principle function in neurons is to reduce 
the potassium conductance, allowing cholinoceptive neurons to become increasingly 
susceptible to other excitatory inputs. Notably, acetylcholine has a slow acting 
neuromodulatory effect that is representative of the gradually modulated, sustained action 
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of the encoding state witnessed in the EC during learning exercises that determines how 
likely an experience is to be recorded or omitted.6 The desire to use acetylcholinesterase 
inhibitors as the first line therapy in those with AD dementia can be better understood in 
the context of this reliance of memory formation on the availability of acetylcholine. 
Alzheimer’s disease pathology 
AD dementia develops from the accumulation of plaques and abnormal proteins that 
interrupt the routine processes and neuronal communication of a healthy brain. These 
plaques consist of a build-up of Ab 42 as a result of either increased protein production in 
earlier onset AD dementia patients or, in later onset cases, from an impaired ability to 
metabolize and extract these plaques. Continued build up interferes with neuronal 
synaptic functioning and the removal of cellular communication propagates cell death. 
The other factor involved in the progression of AD is the formation of neurofibrillary 
tangles (NFT). They are formed from paired helical filament tau (PHFt) that occurs when 
the tau cellular structural support protein becomes hyperphosphorylated in AD. The 
formation and accumulation of NFT in the neuronal cytoplasm inhibit the delivery of 
nutrients and other necessary particles throughout the neuron, leading to neuronal death. 
Put simply, Ab plaques damage neurons externally while NFT cause intracellular 
damage. Together, they lead to multiple changes in the brains of those with Alzheimer’s 
including inflammation and notable cortical shrinking from neuronal cell death,1,8,9 
manifested in confusion and memory loss. 
	7 
Alzheimer’s disease diagnosis 
A diagnosis of AD can be difficult since the cognitive deficits observed can be similar to 
those present in other illnesses. The clinician must distinguish whether the cognitive 
decline in a patient is due to true dementia or a different etiology that is reversible with 
proper treatment, such as depression, delirium, thyroid dysfunction, vitamin deficiencies, 
excessive alcohol use or side effects of medications. Adding to the insidious nature of 
AD, it has been associated with subclinical neurological changes for up to 20 or more 
years prior to overt cognitive symptoms developing.1,10 The importance of early diagnosis 
is emphasized by observations that the best responses to medication are in those still in 
the early stages of the disease. Table 1 shows a detailed description of symptoms 
compared to changes in behavior due to senescence. 
Table 1. Signs of AD or Other Dementias Compared with Typical Age-related 
Changes Organized by the Alzheimer’s Association1 
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	 Genetics, biomarkers and neuroimaging have helped guide the diagnosis of AD 
dementia. AD dementia is linked to the amyloid precursor protein (APP), presenilin 1 
(PSEN1) and presenilin 2 (PSEN2) genes. Goldman et al. go on to elaborate, that having 
a mutation in either APP or PSEN1 genes ensures the development of AD dementia, and 
a mutation in the PSEN2 gene carries a 95% risk of being diagnosed with AD.1,11 The 
Apolipoprotein E e4 gene variation is the second most common variation after the e3 type 
and is more commonly present in those who have AD dementia, though it lacks sufficient 
evidence to suggest its predictive value in diagnosis.1  
Biomarkers are helpful in supporting the diagnosis of AD dementia if clinical 
criteria are met, however, routine screening of biomarkers are not the current standard of 
care. The National Institute on Aging-Alzheimer’s Association stress that AD dementia 
continues to be above all else, a clinically diagnosed neurodegenerative disease.12 
Additionally, the use of biomarkers is limited by a lack of uniformity across clinical 
facilities in the evaluation of biomarkers.12 In AD patients, progression of the disease can 
be monitored through the levels of Ab deposition and tau protein in cerebral spinal fluid 
(CSF), expected to be at low and high concentrations respectively. 
The presence of biomarker changes supporting AD development, can be 
corroborated through imaging modalities such as positron emission tomography (PET) 
through positive imaging of amyloid and diminished fluorodeoxyglucose (FDG) neuronal 
uptake can help bolster an AD diagnosis. Additionally, structural magnetic resonance 
imaging (MRI) modalities would reveal disproportionate atrophy of the medial basal and 
lateral temporal lobes and the medial parietal cortex.12  
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Current pharmacological therapy  
The principal neurotransmitter used to communicate between the structures that 
constitute the memory forming network at the MTL is acetylcholine. As neurons are 
destroyed the availability of acetylcholine and, therefore, the ability to transfer signals 
from one region of the brain to the next to consolidate and establish experiences is 
impaired. Thus, cholinesterase inhibitors, such as donepezil, rivastigmine and 
galantamine, are used to compensate for the decrease in neurotransmitter by delaying the 
breakdown of acetylcholine at the synapse, therefore improving neural communication 
and alleviating dementia symptoms.13  
N-methyl-D-aspartate (NMDA) receptor antagonists, such as Memantine, are also 
used as a treatment option for their potential neuroprotective effects on cortical and 
hippocampal neurons that may undergo damage from overstimulation of NMDA 
receptors by glutamate neurotransmitters. Cowburn et al.14 found that Ab plaque 
fragments have the potential to act as glycine site agonists or partial agonists. NMDA 
receptors are activated by glutamate and glycine neurotransmitters, and, therefore, the 
ability of AD to promote NMDA receptor activation further puts the receptor at risk of 
excitotoxicity.14,15 These medications, however, continue to be unsuccessful in reliably 
slowing or preventing cognitive decline.1,3,13 
Deep brain stimulation 
Deep brain stimulation (DBS) involves the application of an implantable electrical 
stimulation device with the goal of treating neurological disorders. The procedure is 
performed in two phases: first the electrodes or probes are placed in one or both 
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hemispheres of the brain over the cortical region affected by the patient’s neurological 
disease. Next, the electrode wires are guided under the scalp, through the neck and 
connected to an implantable neuro-stimulator device (INS) installed subcutaneously 
under the clavicle. The INS can be programmed externally by the treating physician 
though patients are usually given a remote to adjust the strength of the stimulation and 
shut off the device, if necessary. Another safety feature found in numerous INS devices is 
a magnetic reed switch that enables users to shut down the device by swiping a magnet 
over it in an emergency. The battery life of these devices last approximately three years 
depending on what it is being used to treat and batteries can be replaced as an outpatient 
procedure.16 DBS is capable of producing inhibitory or excitatory effects on neurons of 
the brain, depending on the pathology at hand, and had originally been used for analgesic 
purposes. DBS is usually the last line therapy for illnesses no longer responsive to 
pharmacologic options. Settings for the device tend to be empiric and can be customized 
to the patient as symptoms worsen.17 
DBS has been explored as a treatment option for multiple neurodegenerative 
illnesses. It was used to diminish the symptoms of essential tremor since the late 1980’s. 
Later, DBS was applied to Parkinson’s Disease (PD) in 2002 and dystonia starting in 
2003. Other conditions for which DBS can be used therapeutically include epilepsy, 
obsessive compulsive disorder and depression. In the treatment of PD, DBS is used to 
restore the physiological functions of nerves or muscles by precise and careful delivery of 
electrical stimulation to the subthalamic nucleus and sometimes the ventralis intermedius 
nucleus region of the thalamus. Stimulation of these areas aim to recreate an effective 
	11 
alternative neural circuit to circumvent the abnormal pathological pathway that 
develops.18 By 2014, it was estimated that over 100,000 DBS procedures had been 
performed to treat PD in the United States alone.19  
Due to the invasive nature of DBS treatment, it is important to understand the 
benefits as well as the risk of complications that may follow. Patients who have 
undergone the procedure have only had a 6.5% complication rate involving episodes of 
depression or mania, which were successfully reversed through fine tuning of the 
stimulation parameters. Other complications pertained to mechanics, hemorrhage or 
infection due to the device, in addition to other risks that come with any surgical 
procedure. These occurred in approximately 3% or less of cases,19 supporting its safety 
profile in patients, despite involvement of such a crucial organ. With DBS proving to be 
efficacious against illnesses refractory to pharmacologic interventions and a low 
complication rate, it would be reasonable to adapt DBS to treat other neurological 
conditions such as AD dementia.  
Existing research 
Information to help guide the approach in allocating DBS to another cortical region 
safely, effectively and comfortably for patients can be garnered from studies performed 
prior to its widespread application and data collected from its current use. Research on 
DBS and its effects on memory have primarily been studied in subjects with epilepsy 
resistant to pharmacologic interventions. This particular population of patients are 
recruited often due to the practice of installing electrodes to localize focal seizure zones 
in the brains of these patients. Through the use of electrodes, a cortical lesion can be 
	12 
made or the area can be stimulated to abate seizure activity. This has provided invaluable 
information to the researchers in neurology despite its invasive nature. During a 1985 
experiment,20 when DBS was applied to the amygdala, hippocampus and 
parahippocampal gyrus during information recall exercises, participants had marked 
impairment in their ability to recall information correctly. These were associated with the 
presence of what the authors referred to as afterdischarges, or a surge of increased 
electrical activity in the MTL. In other participants, afterdischarges were detected in other 
areas of the cerebral cortex including contralateral to the region of stimulation. Thus, 
afterdischarges were linked to amnestic features exhibited by subjects and helped to 
explain the postictal symptom of amnesia displayed in patients with epilepsy caused by 
paroxysms localized to the MTL. The authors also proposed that afterdischarges spread 
unpredictably downstream of where it originates, which could cause disruption of other 
cerebral processes. It also carries the potential to confound the results of DBS studies by 
making it more difficult to ensure the precise administration to a specific cortical area. 
Thus in future experiments, stimulation parameters were set such that they remained 
below the threshold for evoking afterdischarges.20,21  
Long-term potentiation (LTP) is an essential process among neurons to 
successfully encode memory and, as such, scientists have been trying to recreate it with 
DBS in an effort to improve information recall in study participants. The physiological 
activity of the hippocampus follows a theta rhythm22 and, accordingly, DBS administered 
in a theta burst pattern has proven to evoke LTP in the hippocampus in multiple animal 
models and later, in humans as well. LTP from theta burst pattern stimulation induced the 
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release of acetylcholine and further provoked synaptic activity and neuronal 
communication for encoding. In rodents, this pattern was shown to be the best approach 
as it reliably produced LTP23 with the additional benefit of increasing hippocampal 
neurogenesis.5 If the latter finding can be recreated in humans, it could potentially allow 
for further improvement of symptoms in the setting of DBS for AD.  
The depth of DBS administration, namely the differing features that make up each 
cortical structure, has been investigated as a factor influencing its efficacy. The central 
nervous system contains both white and gray matter pathways; the exterior most cortices 
are composed of gray matter and the inner most of white matter. Stimulation of white 
matter has proven to be best for larger gains in neuronal and metabolic activity 
downstream of the affected circuits compared to gray matter, which promotes local 
neuronal activity suppression when used.5,24 Thus, electrodes are typically inserted at the 
depth of cortical white matter in DBS surgeries to improve responses to therapy.  
Another important parameter investigated with DBS was the appropriate strength 
of electrical stimulation to provide maximal efficacy while ensuring its tolerance and 
more importantly its safety. In a 1963 study performed by Penfield and Perot, electrical 
stimulation of the temporal lobes provoked subjects to re-experience past memories and 
produced feelings of familiarity.5,25 These feelings of déjà vu were reproduced in 2008 
when Hamani et al. applied DBS to the MTL using low voltages with the intention of 
treating obesity through stimulation of the hypothalamus. Interestingly, similar 
experiences were induced when comparing stimulation of the MTL from the right and 
left hemispheres, showing that both play a role in the storage of memories. As the 
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strength of stimulation was increased, subjects described the contents of their recalled 
experiences as becoming more vivid and detailed. Simultaneously, physical symptoms 
developed as the intensity was strengthened with subjects feeling warm, having visual 
disturbances, facial hyperemia and perspiration. Minimizing symptoms of DBS would 
also help to preserve blinding of patients to stimulation being administered and provide 
more reliable data in subsequent studies.26,27   
 
Figure 2: Papez Circuit within the MTL adapted from Lozano & Lipsman28 
Given that AD is a neurodegenerative disorder with impairments in forming and 
preserving memories, DBS studies for potential therapy have primarily targeted the 
limbic system or Papez circuit, which is a network within the limbic system consisting of 
the cerebral cortex, the hippocampus, the fornix, the cingulate cortex, the thalamus and 
mammillary bodies of the hypothalamus.29,30 The position of some of these structures can 
be seen in Figure 2.28 Particular focus has been placed on the hypothalamus, 
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hippocampus and its components, the fornix and NBM. Though stimulation of the 
hippocampus would be hypothesized to be the region with the greatest potential for 
memory improvements due to its increased activity when LTP and learning tasks are 
being observed, the evidence for its efficacy with respect to cognitive function is mixed 
at best. When testing recognition memory of words, abstract drawings and faces using 
single pulse electrical stimulation, there were sharp declines in recall ability when 
bilateral hippocampi were stimulated simultaneously. Bilateral stimulation under further 
analysis was shown to cause interference in processes limited to application during 
encoding alone; retrieval ability was unaffected when DBS was applied to the 
hippocampus during recognition taks.31 Unilateral hippocampal stimulation did not 
deviate from baseline, however, indicating that the hemispheres can function 
independently.31 DBS at the hippocampus performed by Jacobs et al. was also shown to 
impair recall of learned spatial and verbal memory when compared to a control group.32 
This study, however, found significantly improved memory performance from the 
application of DBS to the parahippocampal gyrus.32 Recall deficits secondary to DBS of 
the hippocampus were once again evident when assessing word and facial recognition, 
though there were no significant effects in object recall ability. This particular experiment 
highlighted the fact that there may be a lateralization of information between hippocampi 
with left hippocampus DBS causing deficits in word recognition and application to the 
right hippocampus affecting facial recognition.33  
 The NBM is the main basal forebrain cholinergic system, making it especially 
susceptible to the pathological changes that follow in the progression of AD. DBS of the 
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NBM conducted bilaterally at a low frequency of 20 Hz, across 12 months, on mild to 
moderate AD participants showed improvements in the Alzheimer’s disease assessment 
subscale-cognitive (ADAS-Cog) score. The Mini-Mental State Examination (MMSE) 
score remained largely unchanged, though it had been declining by 4 points annually with 
pharmacological monotherapy. There were only 2 complications reported but they were 
related to hardware. Of note, participants continued to take their cholinesterase inhibitor 
medications throughout the length of the study. Thus, it is unknown whether DBS of the 
NBM showed promising results due to its role as an adjuvant for the current first line 
treatment or whether it could produce these results without the medications prescribed to 
participants of the study.34  
Neuroplasticity, or the plasticity of the brain, refers to its ability to learn and 
utilize new information presented to it. This is an ability of the brain that is lost in those 
with AD as they decline, secondary to the atrophy of cortical areas taking place as the 
disease progresses.34 When Kuhn et al. saw unchanged cognition scores, they 
hypothesized that the neuroplasticity effect observed after stimulation of the NBM may 
be secondary to the release of neurotrophic factors, which can act as neuronal growth 
factors. Their hypothesis was further supported by the fact that the NBM carries a large 
quantity of neuronal growth factor receptors, in addition to the observed increase in the 
dispersal of these growth factors with a rise in synaptic activity.34 
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Figure 3: The Limbic System Adapted from Waxman35 
Effects of stimulation on the fornix have been recorded as well, which is one of 
several structures that make up the limbic system as seen in Figure 3, along with the 
hippocampus and the hypothalamus.35 Hamani et al. applied DBS to the hypothalamus in 
one subject while investigating treatment for refractory obesity. Electrodes nearest to the 
fornix caused vivid recollection of past memories when stimulation was activated. 
Improvements in verbal learning and spatial associative learning were observed after 3 
weeks of continuous bilateral stimulation. Hamani et al. posited that the outcome of the 
procedure was consistent with inducing activity of the hippocampal memory circuit 
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through indirect stimulation of the fornix.26 The fornix was investigated again in 2016 by 
Lozano et al.27 in a phase 2 trial for treating mild AD subjects. DBS was applied to the 
fornix in a cohort of 42 patients ages 45-85. Continuous DBS was delivered for 12 
months, without adjustment of the stimulation parameters during that period. Benefits 
were exclusive to the older participants. Those younger than 65 years of age showed a 
decline in scores when assessed by the ADAS-Cog 13, whereas those 65 and older 
improved in clinical measures and developed increased glucose metabolism in the brain. 
As AD progresses, cerebral glucose metabolism decreases and, thus, an increase is 
indicative of greater brain function. However, participants showed improved brain 
glucose metabolism that was predominantly limited to the first 6 months of DBS, 
followed by no change for the remaining 6 months. Similar to Kuhn et al.,34  participants 
of this study continued using cholinesterase inhibitors throughout.27   
 The EC is the limbic structure that has repeatedly shown potential benefits when 
activated using DBS. There was an exception however, when Jacobs et al. performed a 
study where participants with stimulation applied to the EC showed impairment when 
carrying out a spatial navigation task. The authors stated that the contradicting results 
compared to those in Suthana et al. (2012), occurred in response to differences in how the 
tasks were organized. The former involved an allocentric exercise, making it difficult for 
subjects to acquire route-based strategies, and the latter involved non-allocentric spatial 
tasks, with a fixed starting location. The studies also differed in how much time DBS was 
applied for, with Jacobs et al. lasting a shorter duration. These 2 studies allude to the need 
for further optimization of DBS methods to ensure memory improvements. Titiz et al. 
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showed evidence of lateralization of the EC with stimulation of the right EC causing 
increased facial recognition in addition to an improved ability to exclude images that 
were similar to the original item during recall tasks. They introduced DBS to the 
participants using the theta burst physiological pattern that has been shown to be highly 
effective for activating LTP. The EC precedes the hippocampus and is linked through a 
white matter bridge known as the angular bundle. This further supports the plausibility 
for improved memory in this study.22 The EC has been described as a crucial component 
of the temporal lobe memory system, supported by its sustained level of activity during 
learning processes. Additionally, it contains the strongest direct cortical projection to the 
hippocampus through the perforant pathway. Its involvement in AD pathology has been 
established by observations of significant neuronal cell loss in the EC at the 
commencement of the illness.6   
 While the majority of research for the role of DBS in facilitating memory 
formation was focused on which area of the brain would be stimulated, Ezzyat et al. 
(2017) explored the additional parameter of DBS administration timing. They postulated 
that, since differences in detectable neural activity could help distinguish whether 
information would be remembered later, intervening through neural stimulation during a 
less efficient encoding state may allow for a better outcome. Using intracranial 
electroencephalography (iEEG), they measured neural activity across the entirety of the 
brain rather than focusing on specific regions, due to the high likelihood of impulses 
spreading outside the stimulation zone. Participants conducted free recall tasks, a 
memory activity that is vulnerable to many neurological deficits, and their neural activity 
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was simultaneously recorded. After collecting the data, they consolidated and calculated 
what they refer to as “classifiers” that would be akin to analyzing neural activity for the 
probability of positive or negative recall. DBS was applied to various locations of the 
MTL during recall tasks, followed by pairing the recorded activity with the classifier 
previously developed. The results showed that DBS applied during more efficient 
encoding caused impairment, whereas recall was enhanced when applied to low encoding 
states in the brain.36 Ezzyat et al. (2018) further investigated the effects identified in their 
previous study involving the use of classifiers for predictive recall outcomes. This time 
they applied DBS to the lateral temporal cortex at predetermined times during encoding 
processes. DBS was programed using the classifiers developed from their new cohort of 
participants. They set thresholds pertaining to declines in encoding so that stimulation 
could be administered to accomplish what they referred to as a rescue response for 
encoding. When recall was tested using this framework, not only was the probability of 
recalled information presented during the stimulation response improved by 15%, 
participants were also more likely to remember items encountered before and after the 
application of DBS.37  
 Ezzyat et al. (2018) introduced an alternative approach for DBS application, 
optimizing timing of stimulation to become more effective to reliably produce improved 
recall. Previous studies of the MTL have suggested that the MTL is the region of the 
brain most directly involved in memory encoding and retrieval, particularly the EC. 
Whereas timing of administration of DBS has mainly been independent of individual 
global neural activity in the brains of AD dementia patients, applying DBS to the EC 
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using the closed-loop approach, that has proven to be successful during low encoding 
periods, may provide an efficacious therapy option for AD.	  
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METHODS 
Study design 
This proposal will investigate the utility of DBS at the EC with cholinesterase inhibitors 
compared to cholinesterase inhibitors alone in patients with mild to moderate AD 
dementia across a 24-month multicenter, double-blind, randomized controlled trial.  
Study population and sampling 
Recruitment of participants will occur across 6 medical centers in Massachusetts where 
DBS procedures are performed. These sites include Boston Medical Center, 
Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and 
Women’s Hospital, Lahey Medical Center and Baystate Medical Center. Participants will 
be organized into classifications of mild to moderate AD dementia using scores attained 
on the MMSE, which assesses 5 cognitive areas: orientation, immediate recall, 
calculation and attention, language, and delayed recall.13 The maximum number of points 
available for each category are 10, 3, 5, 9 and 3 respectively.38 MMSE scores of 20-23, 
16-19, £15 correspond, accordingly, to mild, moderate and severe AD dementia 
classifications.3 The criteria for selection is outlined in Table 2. 
Table 2. Inclusion & Exclusion Criteria for Selecting Participants27,39 
Inclusion  Exclusion  
1. Non-pregnant women and men 
ages 45 to 85  
2. Informed consent by the 
participant, if capable, and/or their 
caregiver 
3. Must have probable dementia 
according to the National Institute 
1. Neuropsychiatric inventory 
(NPI)41 total score ³ 10 or score of 
³ 4 in any domain except apathy 
during screening 
2. Additional screening of Modified 
Hachinski ischemic score > 442 
3. Those at risk of suicide within the 
3 month time span prior to 
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of Aging/Alzheimer’s Association 
criteria27,40 
4. MMSE score between 15 and 23 
(indicating cutoffs for severe and 
mild AD dementia respectively)3 
5. Must have a caregiver or 
informant to reliably report on 
daily activities and functioning 
throughout the study 
6. Cholinesterase inhibitors 
(galantamine, donepezil or 
rivastigmine) must be taken in 
stable doses for a minimum of 60 
days prior to signing consent form 
for study. 
7. Must be a good surgical candidate 
for placement of DBS apparatus as 
determined by neurosurgical team 
screening using the Columbia 
Suicide Severity Rating Scale (C-
SSRS)43 
4. Attempted suicide in the 2 years 
prior to signing consent 
5. History of psychiatric disorder 
other than dementia 
6. Score > 10 on the Cornell Scale 
for Depression and Dementia 
(CSDD)44 during screening 
7. Prior head trauma within 2 years 
of signing consent 
8. Past medical history of brain 
tumor, subdural hematoma or 
other clinically significant space-
occupying lesions on computed 
tomography (CT) or MRI 
9. Mental Retardation 
10. Any abnormal laboratory results, 
neurovascular or cardiovascular 
disorders, or currently prescribed 
non-AD medications that would 
interfere with carrying out the 
study 
11. Any contraindications for use of 
MRI or PET scan, such as 
claustrophobia, metal hardware in 
the body or diagnosis of insulin 
dependent diabetes.  
12. Unwilling or unable to comply 
with study protocols 
13. Life expectancy of under 2 years 
14. Simultaneous enrollment in 
another active clinical trial 
 
 Estimation of the necessary sample size for a two-sided t-test analysis of 
significant changes in ADAS-Cog 13 scores for those with mild to moderate AD 
dementia, will be 107 participants per group, for a total of 214 participants for this study. 
This was calculated using the mean ADAS-Cog 13 scores and standard deviation (3.9) 
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values of DBS (28.6) and non-DBS (27.1) treatment arms in the study performed by 
Lozano et al.,27 an effect size of 0.385, a power of 80% and 5% significance. 
Intervention 
Those who meet the inclusion criteria will be randomized 1:1 using an identical 
technique utilized in the ADvance clinical trial,39 where randomized assignment to either 
the standard therapy plus DBS group or standard therapy alone group will be facilitated 
through an unblinded technician. This same technician will be tasked with programming 
the INS in the corresponding participants. All participants regardless of study arm, 
however, will undergo placement of DBS and recording electrodes. The control group 
will have a sham electrode protocol, identical to the intervention group, though the DBS 
device will not be activated. Sham procedures have been conducted in previous 
studies,27,39 being essential to maintaining the integrity of the collected data since 
portions of the ADAS-Cog 13 are vulnerable to subjective interpretations. Through this 
manner, the surgeons, study coordinators, the principal investigator clinicians 
interviewing at follow up exams, and the participants themselves will remain blinded.27,39 
Participants will receive AdTech Spencer SD 1.12 mm width and PMT Depthalon 0.8mm 
width electrodes placed at the subdural level of cortical surfaces, in addition to deeper 
placement, into the brain parenchyma from which electrophysiological data will be 
collected.37 Clinical teams will place electrode grids in a design that would be suitable for 
localizing epileptic foci with particular placement bilaterally over the MTL so that a 
depth electrode can be installed to target the EC in both hemispheres of the brain. The 
electrodes will be triggered using an INS programmed to stimulate below a preset 
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threshold. The parameters for the device will be attained from individualized 
performances that optimize the classifier’s detection for changes in neural activity.37  
 Due to the delicate nature of neurosurgery, it is imperative to ensure accurate 
cortical placement of the DBS instruments throughout the procedure. Surface regions of 
the cortex will be outlined prior to implant of electrodes and the INS through the use of 
whole brain volumetric T1-weighted MRI scans and methods similar to those used in 
Ezzyat et al. (2018). Other modalities that will be used from their study include dedicated 
hippocampal coronal T2-weighted scan with Advanced Normalization Tools (ANTS) and 
Automatic Segmentation of Hippocampal Subfields multi-atlas segmentation methods. A 
CT scan will be performed after implantation of the electrodes, revealing coordinates of 
radiodense electrode contacts, which will be registered onto MRI scans of the brain using 
ANTS. An energy minimization algorithm will be used to layout subdural electrode 
locations as well. Finally, a neuroradiologist will review cross-sectional images and 
surface renderings to ensure the automated localizations of the previously mentioned 
cortical mapping methods.37 
 To train the classifier to detect encoding efficacy, participants will undergo a 
delayed free recall activity after electrode placement, during which iEEG will be used to 
record neural activity and, consequently, the electrophysiological pattern that predicts 
successful recall of a word. They will be asked to memorize lists of 12 words each, 
randomly selected and without replacement, from a collection of frequently used English 
nouns derived from: http://memory.psych.upenn.edu/WordPools. Each word will remain 
visible for 1,600 ms, followed by a randomly jittered 750-1,000 ms blank inter-stimulus 
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interval. A distractor task involving multiple arithmetic problems will then be presented 
after the last word of each list lasting 20 seconds.37 After the distractor activity, subjects 
will be asked to verbally recall as many words as they can from the initial list of words 
over 30 seconds. Their vocal response will be recorded digitally and manually scored for 
analysis afterwards. Each participant completes a session that is made up of 25 lists of the 
aforementioned encoding-distractor-free recall process. Electrophysiological data will be 
processed and used to construct a classifier individualized for the cortical activity schema 
for each participant,37 along the methodology outlined by Ezzyat et al. (2018). Figure 4 
depicts the process used for constructing the classifier.37 
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Figure 4: Procedure for Calibrating the Classifier Program Designed by Ezzyat et 
al. (2018)37 
The amplitude for stimulation to avoid neural afterdischarges, while maintaining 
its safety profile, was determined for depth and cortical surface contacts to be a 
maximum of 1.5 mA and 3.5 mA respectively by Ezzyat et al. (2018). Similarly, other 
DBS parameters will be determined based on the performance of participants during a 
pre-test with DBS administered at different parameter combinations while the subject is 
not performing an experimental task. By monitoring measurements of neural activity for 
each person during the pre-test through use of the classifier, the combination that 
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produces the greatest recorded change, will be the optimal setting for that participant.37 
The parameter combinations vary in their frequency (10, 25, 50, 100, 200) Hz and 
amplitude (0.25 up to 2.00) mA rising in increments of 0.25 mA while the pulse width 
remains constant at 300 µs. The stimulation will be applied through depth electrodes 
targeting the EC in a charge-balanced biphasic rectangular pulse fashion.  
Using the appropriate parameter combinations producing the best score on the 
pre-test, the closed-loop programming will monitor neural activity across the electrodes 
in place and be setup to administer DBS at the EC for a period lasting 500 ms, at any time 
that it detects poor encoding processes. Neural activity suggesting poor encoding is 
defined as a classifier estimated probability of information recall below 0.5.37 The INS 
will also be programmed to track the number of stimulations it has administered since the 
last assessment, which will be documented at each visit. Participants in the sham arm of 
the study will undergo the same procedure with the exception of application of DBS to 
the EC bilaterally.   
Study variables and measures 
Participants will be divided into sham and DBS groups and progress throughout the 
length of the study will be measured using the ADAS-Cog 13 scores compared to 
baseline scores of each subject. Participants will return one month after implantation to 
evaluate for acute device or procedure related complications reported by either 
themselves or their caregiver. If at any time a serious complication putting the participant 
at risk of any harm or requiring hospitalization for greater than 1 day occurs, that 
particular participant will become unblinded and removed from the study. If possible, the 
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DBS hardware will be removed as soon as it is safe to do so from a surgical perspective. 
Thereafter, subjects will be assessed at 6, 12, 18 and 24 months. ADAS-Cog 13 is a 
modified version of the ADAS-Cog classic and will be used in this study since it adds 
more cognitive domains to assess for the disease impact on participants. The ADAS-Cog 
13 adds a number cancellation and a delayed free recall task to the classic version, 
increasing the total score possible to be 85 points.45 The average annual rate of change for 
the ADAS-Cog 13 is approximately an increase of 8 points.46 The primary outcome will 
be a significant decline in the change from baseline of ADAS-Cog 13 scores between 
both groups, at the end of 2 years. Secondary outcomes include differences in efficacy 
when comparing participants aged above or below 65 years and in mild compared to 
moderate stages of AD. As well as, the association of total number of times DBS was 
delivered, with changes in ADAS-Cog 13 scores over the length of the study.  
Recruitment 
The geriatric and neurology specialties within the 6 medical centers mentioned in the 
Study population and sampling section of this paper will develop a list of potential 
candidates for this study through clinical interviews with patients. These are major 
medical centers that provide care to a large portion of Massachusetts residents. In 
addition to current patients, participants will continue to be recruited through the first 
year of commencing DBS procedures within the study. Should there not be a sufficient 
quantity of candidates to meet the sample size, efforts will be made to recruit from 
medical centers in neighboring states, including Connecticut, New York, New Hampshire 
and Vermont.   
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Clinicians with experience in dementia research and DBS surgery will perform 
initial interviews to assess the patient’s capacity to provide consent. If the clinician 
determines that the patient is of capacity to consent and fully comprehend the 
commitment and potential consequences following the DBS procedure, then the consent 
form will be signed in the presence of the caregiver and cosigned by the caregiver as a 
witness. The participant and caregiver must agree on consent to enroll. The patient may 
lose capacity during the study as a result of AD dementia progression and, thus, this 
method ensures that the caregiver will continue to endorse consent in their stead. 
Similarly, if the patient meets criteria for this study, but lacks capacity to consent, the 
caregiver may consent in their place if they are the active healthcare proxy. To sign the 
consent form assumes that the institution confirms eligibility criteria are all satisfied39.   
Data collection 
Within 30 days of attaining a signed consent for the study, participants will complete a 
baseline ADAS-Cog 13 that evaluates the cognitive domains described in Table 3. The 
next assessment will be performed 30 days after implantation of the DBS apparatus to 
detect any acute complications of the device or surgical procedure. Afterwards, follow up 
assessments will be repeated at 6, 12, 18 and 24 months from implantation using the 
MMSE and ADAS-Cog 13 surveys. Any adverse clinical outcomes related to DBS 
administration or surgical implantation over the course of this study will be reported to 
investigators and a count will be recorded and made available to the public, organized by 
the complication type. 
Table 3: ADAS-Cog 13 Cognitive Domains13,45 
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ADAS-Cog 13 
(Maximum Score of 85) 
1. Spoken language 
2. Comprehension of spoken language  
3. Recall of test instructions 
4. Word finding difficulty 
5. Following commands 
6. Naming objects 
7. Construction drawing 
8. Ideational praxis 
9. Orientation 
10. Word recall 
11. Word recognition 
12. Number cancellation 
13. Delayed word recall 
 
Data analysis 
A two-sided t-test analysis will be used to examine the principal outcome of delaying the 
progression of AD dementia across 2 years through the use of DBS and 
acetylcholinesterase inhibitor dual therapy compared against standard pharmacological 
therapy alone. The mean change in ADAS-Cog 13 score over the length of 2 years for 
each group will be compared; a significant decrease in change within the DBS dual 
therapy arm indicates delayed progression.  
 There are multiple possible factors that may have an effect on clinical outcomes 
and how well a participant responds to therapy, such as the actual number of DBS doses 
each patient received, age,27 or AD stage. To further evaluate these variables, a subgroup 
analysis using a two-sided t-test will be performed. For age, all participants will be 
stratified into 2 groups: 1 group for all those under age 65, representing the early-onset 
AD population, and 1 group made up of people ages 65 and older. For stage of disease, 
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the data for all participants will be stratified into either mild or moderate stage AD, based 
on the MMSE scores at the start of the study. The 2 subgroups will then compare data 
with DBS intervention against the data without DBS therapy within each stratification to 
look for significant differences in ADAS-Cog 13 scores. That is, both age groups will be 
compared to their non-DBS counterpart, likewise, mild and moderate stage AD will be 
compared to their respective non-DBS participant group data. The appropriate means, 
standard deviations and effect size will be calculated from the data collected at the end of 
the clinical trial. For the frequency of DBS delivery, the number of times stimulation was 
triggered will be downloaded from the INS of all subjects at the end of the study. A 
correlation analysis to investigate the relationship between the number of stimulations 
triggered and the rate of decline in ADAS-Cog 13 scores over the length of the study will 
then be performed. 
Timeline and resources 
Table 4: Time Course for Study 
Fall 2018 • Internal Review Board (IRB) and 
FDA submission and approval 
• Recruitment of personnel involved 
in implementing study design 
January 2019 - July 2020 • Recruitment of participants  
• Once approved by the Eligibility 
Review Committee (ERC), 
implantation of DBS and classifier 
training will commence 
July 2019 – July 2021 • Follow up visits for data collection 
are performed after 1 month for 
safety, followed by every 6 months 
thereafter 
Fall 2021 • Analysis of results 
• Completed study to be submitted 
for peer review 
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Table 4 outlines the timeline for this study, beginning with formal submission of this 
proposal to the IRB and FDA for approval. Following approval, personnel including 
researchers, geriatric clinicians, neurology and neurosurgery clinicians, as well as 
neuropsychiatrists will be recruited for each hospital. They will be an integral component 
to the study for data collection and analysis, patient referrals, eligibility screening, and 
patient follow up across all medical centers. Afterwards, rolling recruitment will be 
conducted for 18 months to meet or exceed the estimated sample size needed for analysis, 
with the option to expand recruitment to additional medical facilities if necessary and 
approved by the IRB and FDA. Funding will be procured from the National Institute of 
Health, American Federation for Aging Research, National Institute on Aging, Functional 
Neuromodulation Inc., Medtronic, St. Jude and Pfizer Inc.  
Institutional Review Board 
This study design will be submitted for full review to the Boston University Medical 
Center IRB and the IRB of the 3 additional institutions to ensure the safety and continued 
safety of participants during this novel approach to AD dementia treatment through timed 
DBS.  
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CONCLUSION 
Discussion 
This study aims to overcome the lack of generalizability of the participant population in 
prior studies using DBS. Those studies have been limited to using patients diagnosed 
with epilepsy refractory to medications. Limiting a study to a population with this 
significant comorbidity makes it difficult to produce reliable outcomes as these patients 
may have developed insults to regions of their brain from repeated seizure activity. As a 
consequence this may be putting them at risk of having subclinical functional deficits at 
the neural level and, perhaps more likely, to show decreased benefits from DBS 
therapy.47 Potential obstacles for this study include its invasive nature and extensive list 
of exclusion criteria that may make it difficult to recruit an ample sample size to 
strengthen any significant trends in the data.  
A potential obstacle to this proposed study is the manner in which DBS using a 
classifier has been adapted – without learning multiple lists of words to recall after 
programming the classifier to specifically assess the effect of DBS at decreased encoding 
periods used under Ezzyat et al. (2018). This alteration in method of DBS administration 
makes it difficult to guarantee that DBS will occur as frequently as may be necessary to 
provide improvement or stability in cognition. This experiment is conducted so that if at 
any time, the probability of recalling a learned stimulus decreases below 0.5 according to 
the classifier, DBS will be applied. In daily life however, there are many learning 
opportunities and it is a challenge to ascertain if such opportunities will trigger 
stimulation. To measure this, the quantity of DBS administrations will be logged for 
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those in the active DBS group to ensure that the classifier was reaching its threshold to 
fire and further analysis will help determine what effect, if any, the number of 
stimulations has on AD progression.  
Future studies may look to incorporate free word recall exercises at intervals in 
between the 6 month follow up visits conducted in this study, as it may be beneficial in 
clinical outcomes to ensure a minimum amount of DBS doses administered. Another 
factor that may play a role in delaying the progression of AD dementia and greater 
potential for responding to therapies is the concept of cognitive reserve.1 As it stands, 
increased cognitive reserve is directly related to the number of years of formal education 
received. It also increases with more mentally stimulating professions, which correlates 
with a lower risk of developing AD dementia, in theory, due to an enhanced ability to 
compensate for cognitive decline for an extended period of time. This increased cognitive 
reserve may be analogous to providing treatment early in the disease process of AD since 
it could indicate a greater abundance of intact neural connections, compared to later 
stages. Later studies may choose to investigate what relationship exists between the 
response to DBS therapy and years of education or occupation type among participants. 
Once the location of stimulation and the parameters for DBS have been established, the 
next step in research should investigate its role in monotherapy for AD dementia. Though 
this study is not powered for determining which age groups are the best candidates to 
benefit from DBS therapy, by performing the subgroup analysis using age 65 to separate 
participants, it can serve as a reference point for future studies. Yet this may be limited by 
the lower prevalence of AD dementia that follows with younger populations. Providing 
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treatment for AD dementia earlier in the disease process has proven to be more beneficial 
than later on, though earlier in the disease process is not always correlated to the age of 
the patient. Previous studies have shown that patients above 65 years of age had more 
positive results when compared to those younger than age 65, potentially due to a more 
severe disease process linked to younger onset AD.27 The results of this study may 
reinforce these conclusions by Lozano et al. or perhaps, if the approach for administration 
of DBS presented here is more effective, then comparable maintenance of cognitive 
status will be seen across both age groups. 
Summary 
Currently, a person develops AD dementia every 66 seconds, and by 2050 it is estimated 
to occur as soon as every 33 seconds.1 AD dementia is a debilitating illness that most 
people will develop at some point in their lifetime. Given the disease burden, there is a 
necessity to generate an adequate form of treatment since current pharmacological 
therapies have only provided minor improvements in cognition.3 The success of DBS in 
various neurological pathologies has drawn much attention from researchers seeking a 
more effective treatment of AD dementia. Various regions of the MTL have been 
therapeutically stimulated using DBS in an effort to improve memory function but have 
produced inconsistent results. The numerous methodological variables surrounding the 
use of DBS include the many possible targets in the MTL, the most promising being the 
EC, fornix, nucleus basalis of Meynert and the lateral temporal cortex, and the variables 
that make up the stimulation parameters. These parameters include wave pattern, pulse 
width, amplitude and frequency. Ezzyat et al. (2018) introduced another measure that 
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involved precision in the timing of administration in a closed-loop approach that would 
allow doses of DBS to be triggered in response to real time activity in the brain. This 
study aimed to bridge all these factors together to create an individualized form of 
treatment. Future investigations can use the data collected here and make necessary 
adjustments to establish DBS for AD dementia as a reliable adjuvant to the current 
standard therapy.  
Clinical and/or public health significance 
In the United States for 2016, the estimated cost of care for AD dementia patients 
performed by unpaid caregivers was $230.1 billion, some of which can be found in Table 
5, and the health care costs for the emotional and physical effects on the caregivers was 
estimated at $10.9 billion.1 A novel and substantial therapy for AD dementia to aid in the 
preservation of independence with daily activities for those diagnosed could improve the 
quality of life for both the patient and their caregivers, and lower health care costs that 
are otherwise projected to exponentially increase in the coming years.  
Table 5. Tasks Performed by Caregivers for Those with Dementia Adapted from the 
Alzheimer’s Association (2017)1
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